

## PRESS RELEASE

30 March 2008

### **Aperio Diagnostic Ltd secures further funding**

Aperio Diagnostic Ltd, the company developing real-time diagnostic tools for cervical cancer, has received further significant investment from its shareholders.

The additional funding will enable the company take forward plans for multi-centre clinical trials for its first diagnostic device, aimed at the referral market.

Sameer Kothari, Aperio's CEO, said: "The support from our existing shareholders in this funding round has been excellent. The investment round enables Aperio to press ahead with developing ten referral devices for our multi-centre trial. The referral device will reduce the over-treatment of mild abnormalities of the cervix, help clinicians in accurately pinpointing lesions and provide results to patients in real-time"

Chris Linacre, Director of Service Development for Sheffield Teaching Hospitals NHS Foundation Trust, and a member of Aperio's Board, said: "This latest round of investment is great news for Aperio and will bring commercialization of this technology a step closer."

Existing shareholders include Exomedica Ltd, Medipex Ltd, Sheffield Teaching Hospitals NHS Foundation Trust and BioFusion plc.

***For more information please contact:***

Sameer Kothari, CEO, Aperio Diagnostic Ltd, tel: 0114 222 4580; mobile: 07736 403872

***Notes for editors:***

Aperio Diagnostic Ltd is a company developing the next generation of cancer diagnostics with a product line which will provide real-time diagnostics for cervical cancer. Two products are under development: the first for the referral market and the second for the screening market. Clinical data on 500 women has demonstrated superior performance over existing diagnostic procedures and a multi-centre clinical trial over the next 8 months is expected to underwrite the effectiveness of Aperio's technology and products.

Aperio has developed Electrical Impedance Spectroscopy EIS, an objective scientifically-proven method to differentiate between normal, pre cancerous and cancerous cells. This provides a real-time diagnosis that removes subjectivity at both screening and referral, and potentially avoids the need for a biopsy. Aperio's patented technology, which has been discussed in learned peer-reviewed journals, exploits the different electrical resistivity of normal, pre-cancerous and cancerous cells.

Since incorporation in 2006, Aperio has focused on developing a research-based instrument into a device appropriate for commercial manufacture and routine use by medical practitioners. Both Aperio products consist of a handheld device and a base unit together with a single-use disposable sleeve for each test. Pre-production standard devices will be used in a multi centre clinical trial scheduled to start in Q3 2008.